References
- Pierce DA, Shimizu Y, Preston DL, Vaeth M, Mabuchi K. Studies of the mortality of atomic bomb survivors. Report 12, Part I. Cancer: 1950–1990. Radiat Res 1996;146:1–27.
- Ron E, Preston DL, Mabuchi K, Thompson DE, Soda M. Cancer incidence in atomic bomb survivors. Part IV: Comparison of cancer incidence and mortality. Radiat Res 1994; 137: S98–112
- Thompson DE, Mabuchi K, Ron E, Soda M, Tokunaga M, Ochikubo S, et al. Cancer incidence in atomic bomb survivors. Part II. Solid tumors, 1958–1987. Radiat Res 1994; 137: S17–67
- Darby SC, Reeves G, Key T, Doll R, Stovall M. Mortality in a cohort of women given x-ray therapy for metropathia haemorrhagica. Int J Cancer 1994; 56: 793–801
- Delongchamp RR, Mabuchi K, Yoshimoto Y, Preston DL. Cancer mortality among atomic bomb survivors exposed in utero or as young children, October 1950–May 1992. Radiat Res 1997; 147: 385–95
- Weiss HA, Darby SC, Doll R. Cancer mortality following x-ray treatment for ankylosing spondylitis. Int J Cancer 1994; 59: 327–38
- Boice JD, Jr, Engholm G, Kleinerman RA, Blettner M, Stovall M, Lisco H, et al. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res 1988; 116: 3–55
- Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000; 88: 398–406
- Neugut AI, Ahsan H, Robinson E, Ennis RD. Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. Cancer 1997; 79: 1600–4
- Travis LB, Curtis RE, Boice JD, Jr, Platz CE, Hankey BF, Fraumeni JF, Jr. Second malignant neoplasms among long-term survivors of ovarian cancer. Cancer Res 1996; 56: 1564–70
- Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997; 89: 1429–39
- Preston DL, Shimizu Y, Pierce DA, Suyama A, Mabuchi K. Studies of mortality of atomic bomb survivors. Report 13: solid cancer and noncancer disease mortality: 1950–1997. Radiat Res 2003; 160: 381–407
- Carr ZA, Kleinerman RA, Stovall M, Weinstock RM, Griem ML, Land CE. Malignant neoplasms after radiation therapy for peptic ulcer. Radiat Res 2002; 157: 668–77
- Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995; 87: 524–31
- Kaldor JM, Day NE, Kittelmann B, Pettersson F, Langmark F, Pedersen D, et al. Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a case control study. Int J Cancer 1995; 63: 1–6
- Pawlish KS, Schottenfeld D, Severson R, Montie JE. Risk of multiple primary cancers in prostate cancer patients in the Detroit metropolitan area: a retrospective cohort study. Prostate 1997; 33: 75–86
- Sont WN, Zielinski JM, Ashmore JP, Jiang H, Krewski D, Fair ME, et al. First analysis of cancer incidence and occupational radiation exposure based on the National Dose Registry of Canada. Am J Epidemiol 2001; 153: 309–18
- Mohan AK, Hauptmann M, Freedman DM, Ron E, Matanoski GM, Lubin JH, et al. Cancer and other causes of mortality among radiologic technologists in the United States. Int J Cancer 2003; 103: 259–67
- Sigurdson AJ, Doody MM, Rao RS, Freedman M, Alexander B, Mohan A, et al. Cancer incidence in the US radiologic technologists health study, 1983–1998. Cancer 2003; 97: 3080–9
- United Nations. Sources and effects of ionizing radiation. Vol I: Sources; Vol II: Effects. United Nations Scientific Committee on the Effects of Atomic Radiation, 2000 Report to the General Assembly, with scientific annexes. United Nations sales publication E.00.IX.3 and E.00.IX.4. New York: United Nations; 2000.
- Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 1986; 59: 45–51
- de Vathaire F, Schlumberger M, Delisle MJ, Francese C, Challeton C, de la Genardiére E, et al. Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer 1997; 75: 734–9
- Hall P, Holm LE, Lundell G, Bjelkengren G, Larsson LG, Lindberg S, et al. Cancer risks in thyroid cancer patients. Br J Cancer 1991; 64: 159–63
- Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003; 89: 1638–44